Sign in

You're signed outSign in or to get full access.

PI

Pulmatrix, Inc. (PULM)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 was operationally quiet and financially minimal, as Pulmatrix focused on advancing the Cullgen merger and divesting legacy iSPERSE-based assets; cash ended Q4 at $9.5M, down from $10.8M in Q3 and $19.2M at YE 2023 .
  • The company reiterated plans to close the Cullgen merger in H1 2025 and to divest PUR3100, PUR1800, and the iSPERSE patent portfolio; this strategic pivot is the primary near-term stock catalyst .
  • Q4 revenue was de minimis ($0.003M*) with net loss improving sequentially as operating costs fell; annual 2024 revenue rose to $7.8M on a Cipla contract modification catch-up, while R&D fell materially YoY due to PUR1900 wind-down .
  • Cash runway commentary changed: Q2/Q3 guided “into Q4 2026” while Q4 stated cash sufficient “at least through” the anticipated Cullgen close—implying a shorter horizon as strategic actions take precedence .

What Went Well and What Went Wrong

What Went Well

  • Strategic repositioning progressed: announced merger agreement with Cullgen to create a Nasdaq-listed targeted protein degradation platform with multiple Phase 1 programs—key transformation theme for equity holders .
  • Successful clinical program wind-down reduced R&D spend: 2024 R&D fell to $7.2M from $15.5M in 2023 driven by PUR1900 wind-down and cost actions .
  • Management focus and clarity: “Our focus in the fourth quarter has been to advance the proposed merger with Cullgen… Pulmatrix is in a process to divest its clinical assets, including iSPERSE™ and our Phase 2 ready acute migraine product.” — Peter Ludlum, Interim CEO .

What Went Wrong

  • Revenue softness continued with Q4 revenue at $0.003M*, reflecting minimal reimbursable activity as PUR1900 wind-down completed and assets moved toward divestment .
  • Non-recurring write-down: recognized a $2.6M loss related to the MannKind transactions in 2024, dragging operating results .
  • Cash drawdown: cash and equivalents fell to $9.5M at YE 2024 from $19.2M at YE 2023, limiting standalone optionality without the strategic transaction .

Financial Results

Quarterly Financials (oldest → newest)

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$1.552 $0.366 $0.003
Net Income ($USD Millions)$(5.811)*$(2.587)*$(1.986)*
Diluted EPS ($USD)$(1.59)*$(0.71)*$(0.54)*
EBIT ($USD Millions)$(3.283)*$(2.657)*$(1.952)*
EBITDA ($USD Millions)$(3.236)*$(2.657)*$(1.952)*
Total Operating Expenses ($USD Millions)$4.835*$3.023 $1.955*
Cash and Equivalents ($USD Millions)$12.379 $10.782 $9.521

Notes: Asterisk denotes values retrieved from S&P Global (lacking direct document citations). Values retrieved from S&P Global.

YoY Comparison (Q4)

MetricQ4 2023Q4 2024
Revenue ($USD Millions)$2.202*$0.003
Net Income ($USD Millions)$(2.083)*$(1.986)*
Diluted EPS ($USD)$(0.57)*$(0.54)*
Cash and Equivalents ($USD Millions)$19.173 $9.521

Notes: Asterisk denotes values retrieved from S&P Global (lacking direct document citations). Values retrieved from S&P Global.

Segment Breakdown

  • Not applicable; Pulmatrix does not report revenue by operating segment .

KPIs (qualitative/operational)

  • PUR1900 wind-down complete; Pulmatrix bears no further financial responsibility and will receive 2% royalties on any potential future net sales by Cipla ex-US; monetization to be pursued in the US .
  • iSPERSE IP: ~149 granted patents and ~50 applications as of 12/31/2024 .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayCorporate“Sufficient to fund operations into Q4 2026” (Q2/Q3 2024) “Sufficient to fund operations at least through anticipated Cullgen merger close” (H1 2025) Lowered/shortened horizon
Merger Close TimingCorporateN/AAnticipated close in H1 2025, subject to conditions New guidance
Asset DivestmentsCorporateExploring strategic alternatives Intends to divest PUR3100, PUR1800, iSPERSE portfolio Formalized divestment plan

No formal revenue/EPS/OpEx guidance ranges were provided .

Earnings Call Themes & Trends

No Q4 2024 earnings call transcript was found in our document catalog; themes below reflect press releases.

TopicPrevious Mentions (Q2/Q3 2024)Current Period (Q4 2024)Trend
Strategic alternatives / mergerPursuing strategic alternatives; MannKind transactions closed Announced Cullgen merger; close anticipated H1 2025 Escalated to definitive transaction
Asset monetization/divestmentConsidered partnerships for PUR3100; monetize PUR1800 Intends to divest PUR3100/PUR1800/iSPERSE Accelerated divestment plan
PUR1900 programEnrollment stopped; wind-down ongoing/complete Wind-down complete; 2% ex-US royalty; monetize US Transitioned to royalty/monetization
MannKind cross-licenseAgreements closed; validated iSPERSE; write-down noted $2.6M loss recognized for the transactions Accounting impact realized
Cash runwayInto Q4 2026 At least through anticipated Cullgen close Shortened horizon, tied to deal timing

Management Commentary

  • “Our focus in the fourth quarter has been to advance the proposed merger with Cullgen… If successful, the proposed merger would create a Nasdaq-listed company focusing on targeted protein degradation technology… As part of the proposed merger, Pulmatrix is in a process to divest its clinical assets, including iSPERSE™ and our Phase 2 ready acute migraine product.” — Peter Ludlum, Interim CEO .
  • “Revenues increased… to $7.8 million for the year ended December 31, 2024… primarily related to a contract modification of the Cipla Agreement which resulted in a cumulative catch-up adjustment…” .
  • “Research and development expenses decreased… to $7.2 million… due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company’s lab and facilities lease and employee terminations.” .

Q&A Highlights

  • No Q4 2024 earnings call transcript was available; no Q&A to summarize in our dataset [SearchDocuments: none found].

Estimates Context

  • S&P Global consensus estimates for Q4 2024 EPS and revenue were unavailable in our query, so we cannot assess beat/miss vs Street for the quarter. Values retrieved from S&P Global.
  • Actuals: Revenue $0.003M; Diluted EPS $(0.54)*; where the asterisk denotes S&P Global-sourced figure .

Key Takeaways for Investors

  • The Cullgen merger and associated divestments are the dominant near-term narrative; closing in H1 2025 would reset the equity story to targeted protein degradation with multiple clinical programs—key potential stock catalyst .
  • Operating model shift to virtual and program wind-downs materially reduced R&D and OpEx, improving sequential losses; however, minimal Q4 revenue reflects limited reimbursable activity post PUR1900 wind-down .
  • Cash fell to $9.5M at YE 2024; guidance now ties runway to merger close rather than multi-year horizon—transaction execution risk is the principal focus .
  • The $2.6M MannKind-related loss is non-recurring but highlights the accounting impacts of portfolio reshaping; future royalties and potential monetization of PUR1900/iSPERSE could provide non-dilutive upside if realized .
  • With Street consensus unavailable, estimate recalibration will follow greater clarity on merger timing, asset sale proceeds/dividends, and post-close capital structure and pipeline priorities. Values retrieved from S&P Global.
  • Trading lens: headlines around merger approvals/closing, asset sale progress, and any special dividend details are likely to drive near-term volatility; lack of operating catalysts near-term suggests event-driven positioning .
  • Medium-term thesis depends on Cullgen’s clinical execution and funding profile; the combined ~$65M cash expected at close (per merger PR) and degrader pipeline breadth could re-rate the equity on clinical milestones through 2026 .